vs
Garrett Motion Inc.（GTX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Garrett Motion Inc.的季度营收约是Revvity的1.2倍（$891.0M vs $772.1M），Revvity净利率更高（12.7% vs 9.4%，领先3.3%），Revvity同比增速更快（5.9% vs 5.6%），Revvity自由现金流更多（$161.8M vs $78.0M），过去两年Revvity的营收复合增速更高（9.0% vs -1.3%）
盖瑞特动力（前身为霍尼韦尔交通系统部及霍尼韦尔涡轮增压技术部）是一家美国企业，核心业务为涡轮增压器及相关强制进气系统的工程研发与生产，产品覆盖小型乘用车、大型卡车、工业设备及工程机械等各类陆上交通工具，其前身可追溯至1954年亚利桑那州凤凰城的 Garrett AiResearch 工业部门。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GTX vs RVTY — 直观对比
营收规模更大
GTX
是对方的1.2倍
$772.1M
营收增速更快
RVTY
高出0.3%
5.6%
净利率更高
RVTY
高出3.3%
9.4%
自由现金流更多
RVTY
多$83.8M
$78.0M
两年增速更快
RVTY
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $891.0M | $772.1M |
| 净利润 | $84.0M | $98.4M |
| 毛利率 | 20.8% | — |
| 营业利润率 | 11.6% | 14.5% |
| 净利率 | 9.4% | 12.7% |
| 营收同比 | 5.6% | 5.9% |
| 净利润同比 | -16.0% | 3.9% |
| 每股收益（稀释后） | $0.42 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTXRVTY
| Q4 25 | $891.0M | $772.1M | ||
| Q3 25 | $902.0M | $698.9M | ||
| Q2 25 | $913.0M | $720.3M | ||
| Q1 25 | $878.0M | $664.8M | ||
| Q4 24 | $844.0M | $729.4M | ||
| Q3 24 | $826.0M | $684.0M | ||
| Q2 24 | $890.0M | $691.7M | ||
| Q1 24 | $915.0M | $649.9M |
净利润GTXRVTY
| Q4 25 | $84.0M | $98.4M | ||
| Q3 25 | $77.0M | $46.7M | ||
| Q2 25 | $87.0M | $53.9M | ||
| Q1 25 | $62.0M | $42.2M | ||
| Q4 24 | $100.0M | $94.6M | ||
| Q3 24 | $52.0M | $94.4M | ||
| Q2 24 | $64.0M | $55.4M | ||
| Q1 24 | $66.0M | $26.0M |
毛利率GTXRVTY
| Q4 25 | 20.8% | — | ||
| Q3 25 | 20.6% | 53.6% | ||
| Q2 25 | 19.8% | 54.5% | ||
| Q1 25 | 20.4% | 56.5% | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 20.1% | 56.3% | ||
| Q2 24 | 20.8% | 55.7% | ||
| Q1 24 | 18.8% | 54.6% |
营业利润率GTXRVTY
| Q4 25 | 11.6% | 14.5% | ||
| Q3 25 | 11.3% | 11.7% | ||
| Q2 25 | 11.2% | 12.6% | ||
| Q1 25 | 9.7% | 10.9% | ||
| Q4 24 | 11.7% | 16.3% | ||
| Q3 24 | 9.2% | 14.3% | ||
| Q2 24 | 9.8% | 12.4% | ||
| Q1 24 | 8.9% | 6.8% |
净利率GTXRVTY
| Q4 25 | 9.4% | 12.7% | ||
| Q3 25 | 8.5% | 6.7% | ||
| Q2 25 | 9.5% | 7.5% | ||
| Q1 25 | 7.1% | 6.4% | ||
| Q4 24 | 11.8% | 13.0% | ||
| Q3 24 | 6.3% | 13.8% | ||
| Q2 24 | 7.2% | 8.0% | ||
| Q1 24 | 7.2% | 4.0% |
每股收益（稀释后）GTXRVTY
| Q4 25 | $0.42 | $0.86 | ||
| Q3 25 | $0.38 | $0.40 | ||
| Q2 25 | $0.42 | $0.46 | ||
| Q1 25 | $0.30 | $0.35 | ||
| Q4 24 | $0.46 | $0.77 | ||
| Q3 24 | $0.24 | $0.77 | ||
| Q2 24 | $0.28 | $0.45 | ||
| Q1 24 | $0.28 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-802.0M | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GTXRVTY
| Q4 25 | $177.0M | $919.9M | ||
| Q3 25 | $230.0M | $931.4M | ||
| Q2 25 | $232.0M | $991.8M | ||
| Q1 25 | $130.0M | $1.1B | ||
| Q4 24 | $125.0M | $1.2B | ||
| Q3 24 | $96.0M | $1.2B | ||
| Q2 24 | $98.0M | $2.0B | ||
| Q1 24 | $196.0M | $1.7B |
股东权益GTXRVTY
| Q4 25 | $-802.0M | $7.3B | ||
| Q3 25 | $-813.0M | $7.4B | ||
| Q2 25 | $-812.0M | $7.6B | ||
| Q1 25 | $-700.0M | $7.6B | ||
| Q4 24 | $-673.0M | $7.7B | ||
| Q3 24 | $-778.0M | $7.9B | ||
| Q2 24 | $-725.0M | $7.9B | ||
| Q1 24 | $-735.0M | $7.8B |
总资产GTXRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.4B | $12.1B | ||
| Q2 25 | $2.4B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.2B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B | ||
| Q1 24 | $2.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $78.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.8% | 21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.18× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $341.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GTXRVTY
| Q4 25 | $99.0M | $182.0M | ||
| Q3 25 | $100.0M | $138.5M | ||
| Q2 25 | $158.0M | $134.3M | ||
| Q1 25 | $56.0M | $128.2M | ||
| Q4 24 | $131.0M | $174.2M | ||
| Q3 24 | $67.0M | $147.9M | ||
| Q2 24 | $126.0M | $158.6M | ||
| Q1 24 | $84.0M | $147.6M |
自由现金流GTXRVTY
| Q4 25 | $78.0M | $161.8M | ||
| Q3 25 | $90.0M | $120.0M | ||
| Q2 25 | $143.0M | $115.5M | ||
| Q1 25 | $30.0M | $112.2M | ||
| Q4 24 | $109.0M | $149.8M | ||
| Q3 24 | $47.0M | $125.6M | ||
| Q2 24 | $109.0M | $136.6M | ||
| Q1 24 | $52.0M | $129.7M |
自由现金流率GTXRVTY
| Q4 25 | 8.8% | 21.0% | ||
| Q3 25 | 10.0% | 17.2% | ||
| Q2 25 | 15.7% | 16.0% | ||
| Q1 25 | 3.4% | 16.9% | ||
| Q4 24 | 12.9% | 20.5% | ||
| Q3 24 | 5.7% | 18.4% | ||
| Q2 24 | 12.2% | 19.7% | ||
| Q1 24 | 5.7% | 20.0% |
资本支出强度GTXRVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 3.0% | 2.4% | ||
| Q4 24 | 2.6% | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 3.5% | 2.7% |
现金转化率GTXRVTY
| Q4 25 | 1.18× | 1.85× | ||
| Q3 25 | 1.30× | 2.97× | ||
| Q2 25 | 1.82× | 2.49× | ||
| Q1 25 | 0.90× | 3.03× | ||
| Q4 24 | 1.31× | 1.84× | ||
| Q3 24 | 1.29× | 1.57× | ||
| Q2 24 | 1.97× | 2.87× | ||
| Q1 24 | 1.27× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTX
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
